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Abstract
Background: Young women exposed to a high hereditary breast and ovarian cancer (HBOC) risk are particularly
vulnerable. They are ignored by health prevention measures but exposed to a stream of contradictory information
(medicine, media, Internet). They may feel concerned about surgical prevention issues at a key moment of their
identity construction (self, relationship, sexuality). We designed a special psychoeducational intervention to help
these women cope better with these difficulties.
Methods/design: The BRACAVENIR study consists of a prospective, randomized superiority phase II trial with a wait
list control group. Participants are childless young female counselees (aged 18–30 years) seen at the oncogenetics
department of the Centre Jean Perrin and belonging to HBOC families either with or without BRCA mutations. They
will be invited to attend a weekend group session at a spa resort and to participate in short expert conferences
and focus group activities (group sharing, Moreno role game) supervised by a psychotherapist. Two sessions
separated by a 6-month delay (wait list) will enable us to evaluate the intervention’s effect by comparing questionnaire
scores between the 6-month time points. The main endpoint is an increase of the Herth Hope Index by at least 1 SD.
Secondary endpoints are self-esteem, anxiety trait, anxiety state, coping, and quality of life. With a one-sided α = 0.05
and β = 0.20, 12 participants will be needed by group, plus an additional 2 in anticipation of dropouts. Participants will
be randomized 1:1 to the first or the second session so that the groups will be comparable.
Discussion: The intent of this trial is to bridge the gap on a psychosocial level in these young women with HBOC. A
particularity of the design is the use of a waiting list, which should allow for avoiding major bias. The intervention
consists of a short session that could be proposed to other young counselees if successful. The results may bring
complementary information to facilitate the intervention and also influence the contents of the oncogenetic
consultation.
Trial registration: Ethics committee CPP SUD-EST-6: IRB00008526. Registered on 18 March 2016.
ClinicalTrials.gov identifier: NCT02705924. Registered on 2 March 2016.
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Background
Carriers of mutations favoring the development of can-
cer in adulthood encounter various life difficulties. In
addition to an increasing cancer risk with age, many
questions arise concerning the future and how to build
long-term projects. Although prevention and medical
screening receive great support from health institutions,
most psychosocial consequences remain unanswered.
Among members of cancer-prone families, some are ig-
nored by health systems, in particular the youngest
women exposed to a high risk for breast and ovarian
cancer. Indeed, these women are too young to be con-
cerned with prevention measures. However, some of
them have already been confronted by a mother’s disease
and experienced their mothers’ early death. This early
period of their lives also makes them vulnerable as they
face identity issues, the onset of romantic relationships,
or questions about how to plan for procreation [1, 2].
In parallel, these young women stand in the cross fire
of an abundance of contradictory information spread by
the media, websites, or internet forums. The rapid evolu-
tion of medicine adds to this cacophony in terms of pos-
sible prophylactic surgery, assisted procreation, embryo
selection, and gene therapies, with discordant voices be-
tween specialists, even in Western countries. Unfortunately,
prophylactic interventions directly address the intimate
sphere of these young women who are still maturing.
In many families, the mutations responsible for cancer
risk are known (mainly BRCA1/2), giving to descendants
one of two chances of having a mutation. In other families,
no specific mutation can be diagnosed, and it is impossible
to know for sure whether a family member carries a muta-
tion. Such uncertainty makes communication with relatives
or friends more complex, in particular when one tries to
transmit oncogenetic information [3]. Consequently, a pos-
sible reaction to this incertitude may consist in denial, with
a probable reduction of prevention efficacy.
Socioeconomic difficulties are a known cause of refusal
of medical care [4]. This is also true for cancer preven-
tion. Such difficulties represent an additional burden for
some, although most medical care in France is cost-free
for patients.
It is therefore very important to propose new strategies
to communicate with young counselees in oncogenetics.
We thus developed a psychoeducational intervention
tailored for these young women and decided to test its
efficacy in a prospective phase II trial. In this article, we
describe the content of the intervention and the method
to provide evidence of its interest.
Methods
Objectives
The main objective of this trial is to change the expecta-
tions and improve the coping of young women exposed to
a high risk of hereditary breast and ovarian cancer (HBOC).
Changes of expectations have been chosen as the first ob-
jective, while coping modifications have been placed within
the secondary objectives. We expect that, given the type of
information that will be provided during sessions, expecta-
tions may vary faster than coping manners, the former
seeming more sensitive to information renewal.
Other secondary objectives are:
 To promote a better understanding of oncogenetic
information
 To study if socioeducational differences may limit
overall compliance with medical screening and if
better social communication may help prevent
refusal of care
 To help these young women to build a more
satisfying self-image
 To facilitate the way these young women resolve life
issues such as marital relationships and procreation
planning, and so to favor their emotional and sexual
fulfillment
 To improve the chances of achieving a better long-
term quality of life (QoL)
 To improve adherence to medical screening
Psychoeducational intervention
The intervention will consist of a group session of a
dozen participants at a spa center during a weekend.
Participants will arrive on a Friday evening. After dinner,
a television documentary about the story of a family with
BRCA mutation will be shown. During the following
2 days, besides free spa activities available in the center,
participants will attend ten small conferences lasting
15–30 minutes each. Experts will present the state of the
art in various domains, including the following:
 Latest knowledge in oncogenetics (presented by an
oncogeneticist possessing doctoral and medical
degrees who is also an academic researcher in this
domain)
 Recommendations and morbidity of prophylactic
breast surgery and adnexectomy (presented by a
surgeon specialist in gyneco-oncology)
 Psychological aspects in oncogenetics (presented by
a clinician psychologist possessing a master of
science degree)
 Epidemiology of HBOC and comparative mortality
risks with other syndromes or life habits: how one
can reduce cancer risk (e.g., tobacco, alcohol,
breastfeeding) (presented by a statistician possessing
a master of science degree)
 Good methods of breast cancer prevention
(presented by a medical doctor who is a clinician
senologist responsible for breast cancer screening)
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 Assisted medical procreation and embryo selection
(presented by a clinician possessing medical and
doctoral degrees and specializing in this domain)
 Importance of nutrition and physical activity as risk
modulators (presented by an academic researcher
possessing medical and doctoral degrees and a
nutritionist)
 Description of the assistance program developed to
help counselees exposed to a high cancer risk
(HBOC, Lynch syndrome) following their medical
screening (presented by an oncogenetic counselor as
well as a clinical nurse specialist)
 Health insurance facilities and social financial
support (presented by a professional social worker)
For 15 minutes after each conference, participants will
be able to comment on what they heard and/or to ask
questions of the experts.
The remaining time after this preliminary information
(i.e., about a half of the weekend) will be devoted to
group activities, in particular role-playing games (Moreno
psychodrama approach [5]) and group sharing under the
supervision of a psychotherapist. The psychodrama will
start with a short presentation of the rules: general em-
pathy, no acting, and no after-session talking or gossiping
about what happened or what was said, in particular nam-
ing participants, as well as silence when a role-play is on-
going. The second step asks participants to volunteer and
stage a particular concern or difficulty that they would like
to “treat.” If several persons volunteer, an election is
undertaken to select the topic appearing most important
to the majority of participants. If no one volunteers, the
process starts with a “sticker game” with a theme such as
“what I think of your mutation.” Each participant has to
write on a small paper a short sentence (corresponding to
the theme) describing what she may feel about another
participant and sticks it on the latter’s forehead. Once all
labels are stuck, all participants sit back in a circle and,
one after another, each unglues her sentence, reads it
aloud, and comments on it. Depending on the emotions
raised during this exercise, a theme will be chosen for the
psychodrama and role-played by participants under the
regulation or direction of the psychotherapist. The se-
lected participant explains the situation she selected,
including the protagonists, the details of the event,
and the difficulties she faces, and then chooses an-
other participant to play her role. The stage director
organizes the replay, promotes dialogue, invites stand-
ing in, enriches the drama, sheds light on dark zones,
and proposes alternatives. If the game happens to be
short, another “drama” can be introduced and played.
About 3 h will be devoted to this exercise and the
group sharing just afterward, leaving some time for
spa activities before dinner.
We expect that the greatest effect of our intervention
on expectations and coping will rely on how participants
integrate the delivered information and how the exer-
cises enable them to objectivize difficulties and suggest
possible solutions. Such an intervention, if it is to be
generalized, would induce numerous costs: the weekend
session in a spa center (2½ days), experts’ fees, transpor-
tation of participants and experts, psychologists’ time,
and organization costs. Overall, these costs would repre-
sent about $600 per participant (excluding data manage-
ment, study design, and analysis).
Study design
The study is a randomized, prospective, monocenter,
psychoeducational phase II trial comparing the evolution
of indicators between preintervention and 6 months
postintervention. Two groups will be compared: a first
group of asymptomatic participants who will attend the
session immediately and a second group corresponding
to the “waiting list” (control group). The waiting list ses-
sion will occur 6 months later than that for the first group.
Measured indicators will be obtained 2 weeks before and
6 months after the first intervention for all participants,
whatever their allocation group (Table 1). This will be pos-
sible because the questionnaires will be completed by par-
ticipants at home on a dedicated website. Groups will
therefore be comparable, and the only difference between
them will be limited to the intervention.
In March 2016, the study was approved by the local
ethics committee (CPP SUD-EST-6: IRB00008526) and
registered with ClinicalTrials.gov (NCT02705924).
Population
Participants must belong to HBOC families, be aged
between 18 and 30 years, be single, and be childless
without any personal history of cancer. They must have
consulted at the oncogenetics department of the Jean
Perrin comprehensive cancer center (CCC) and must
been tested for the presence of germline BRCA muta-
tions. If a familial germline BRCA mutation has already
been diagnosed, these women must carry the familial
mutation. If no known deleterious mutation has yet been
found within the family, these women may be included
if their familial risk is high (Eisinger score ≥6 or
Manchester score ≥16) [6–8]. To limit travel costs,
participants must live in the Auvergne region (central
France). Participants must also sign an informed consent
form before inclusion.
Exclusion criteria include pregnant women and those
who cannot answer questionnaires either because of lan-
guage difficulties or because they cannot write in French
correctly. Counselees who cannot connect to the dedi-
cated website will also be excluded, but this is not likely
to happen. Psychiatric disorders and/or ongoing related
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treatments will also result in exclusion, as will any treat-
ment incompatible with a 2-day stay in a spa center.
Recruitment and planning
Since 1988, the oncogenetics department of Jean Perrin
CCC has been collecting pedigree information of
cancer-prone families. Today, more than 7000 families
are registered in the database, which comprises more
than 170,000 members overall. The birthdate and ad-
dress of counselees are recorded, in addition to the type
of cancer risk and various medical annotations (in par-
ticular cancer history of the family members).
Individuals meeting the inclusion criteria will be ex-
tracted from the database, and invitations will be sent by
mail to a randomly selected subgroup of 60 counselees.
The first 28 young women answering positively to this
invitation will be asked to consult at the oncogenetics
department to receive a detailed description of the
protocol and sign an informed consent form, by which
they will agree to participate in the trial. After their consent
is obtained, the participants will be randomized for alloca-
tion to the first or second weekend session. They will also
receive a training course to enable them to complete the
questionnaires using the dedicated website. The overall
organization of the trial is displayed in Table 1.
Randomization
Participants will be randomized 1:1 to the first or second
session (intersession delay = 6 months) using a
minimization technique and stratified according to the
existence or absence of a familial BRCA mutation. We
assumed that this characteristic might induce variations
in coping and expectations and thus alter the impact of
the psychoeducational intervention if the studied
population were not balanced with regard to this
characteristic.
Evaluation criteria
Endpoints and their evolution will be evaluated using
self-questionnaires. To obtain relevant data, these ques-
tionnaires needed to match several criteria:
 Expectations, personality traits and coping strategies
likely correlate, so a hierarchy between these
psychosocial variables was necessary to prioritize
our objectives. Many questionnaires could have been
selected for investigation of the relevant psychological
dimensions, but their number had to be limited to the
necessary minimum so that the time for questionnaire
completion would not take too much time and the
rate of missing data would be acceptable.
 Because they are too young, participants that we
accrue do not naturally focus on cancer and other
health issues. We thus wanted to avoid as much as
possible questionnaires that target mainly health
domains.
 Questionnaires had to be validated and translated
into French.
Figure 1 depicts the construct of our psychological
model and the questionnaires used at each level.
The various endpoints evaluated in our protocol start
from personality traits characterizing our young coun-
selees that can be considered stable: self-esteem and trait
anxiety belong to this category. We rejected any
characterization of other general personality traits and/
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or psychiatric disorders, considering that such topics,
too distant from our objectives, should be of limited in-
fluence on our endpoints (because of the study selection
criteria) and would provide variables with too large a
range of categories that our study would not efficiently
handle (too small a sample size).
Two questionnaires evaluate personality traits: the
Self-Esteem Scale (SES) [9] and the State-Trait Anxiety
Inventory (STAI)-B for the rather stable anxiety trait
[10, 11]. At the second level, coping is examined
using the Ways of Coping Checklist (WCC), the ways
of coping described by Folkman and Lazarus [12, 13].
Resulting from interactions and feedback between the
individual and the environment, perceived control is a
pivotal concept. Levenson [14] has shown that it has
three aspects: a locus of control originating in the
self, and another one located outside the individual
with two possible sources: fate/luck and “powerful
others.” For our counselees, we might wonder if
HBOC predisposition is considered an inner or outer
locus and if an unknown mutation could boost the
“fate/chance” dimension. In young women, the locus
of control may influence two further labile dimensions:
anxiety (state) on the one hand, and expectations on the
other. We will evaluate state anxiety using the STAI-A,
while expectations will be explored with the Herth Hope
Index (HHI) [15, 16]. The overall outcome of this con-
struct in interaction with standard education and/or
socioeconomic levels will be estimated using the
World Health Organization Quality of Life (WHOQOL)
generalist questionnaire [17]. All of these questionnaires
are detailed below.
Herth Hope Index
With the HHI [15, 16], expectations can be split into
two “spheres” [18]: first a factual, concrete level; second,
a subjective one that includes optimism/pessimism, con-
fidence, and the feeling that life makes sense. The first
sphere includes the possible evolution of science that
will perhaps someday discover remedies against cancers
and genetic predispositions. We did not plan to investi-
gate this sphere on which individuals have no influence.
The second sphere is more interesting for our purposes:
We expect that with adequate and positive information,
the confidence in the future of our young women will
grow and that they will be able to build projects more
easily. Rustøen et al. [19] reported that, among newly di-
agnosed cancer patients, hope could be improved by
using a short psychoeducational intervention, although
the improvement for their patients did not persist
6 months later, nor did it seem to influence QoL. Our
hypothesis is that such persistence in asymptomatic
young adults may last 6 months or more, and this is our
main endpoint.
The HHI fits this second sphere of expectations. It has
demonstrated very good psychometric qualities, in par-
ticular among cancer patients, among whom hope ap-
pears to be a basic mechanism involved in coping [16].
Phillips-Salimi et al. [20] proved the validity of the HHI
in adolescents and young adults with cancer. We think it
is well adapted to our young participants in particular
because it is not health-oriented; it will not echo in
young women with HBOC a future possible disease and
therefore will not risk stressing them uselessly. In a dif-
ferent domain, hope management has demonstrated
some efficacy in the prognosis of cardiovascular disease
[21]. This conclusion let the authors propose a five-step
management plan to maintain hope within a transition
framework: (1) acknowledging the changing of life cir-
cumstances, (2) restructuring reality, (3) dealing with
vulnerability, (4) achieving normalization, and (5) resolv-
ing uncertainty” [22]. Our intervention will deal with the
four last steps.
Another advantage of the HHI is its short format: It
contains only 12 simple proposals quoted using a 4-point
Likert scale, ranking from 1 = strongly disagree to 4 =
strongly agree. Its internal structure is composed of three
dimensions: temporality and future, positive readiness and
expectancy, and social/spiritual connectedness [23]. Al-
though we expect that our intervention may improve pref-
erentially the first two dimensions, the global score will
constitute our primary endpoint (sum of all 12 items, but
items 3 and 6 reversed). This questionnaire has been
Fig. 1 Construct of the psychological model enabling the evaluation
of the study endpoints. HHI Herth Hope Index, IPC Internal, Powerful
Others, and Chance Locus of Control Scales, QoL Quality of life, SES
Self-Esteem Scale, STAI State-Trait Anxiety Inventory, WCC Ways of
Coping Checklist, WHOQOL World Health Organization Quality of
Life questionnaire
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translated and validated in French by Lafrance [24]. It will
be used to evaluate the primary endpoint; the other
questionnaires described below will be used to evaluate
secondary endpoints.
Self-Esteem Scale
The SES [9] is a short, ten-item questionnaire that eval-
uates global self-worth by questioning positive and nega-
tive feelings about the self. The origin of self-esteem
seems to be composite and may be searched in early
childhood, parental models, and context favoring per-
sonal development (e.g., parental concern, education,
sports participation). The unidimensionality of the scale
seems demonstrated, although all items are not weighted
equally in the construct analysis [25]. Self-esteem appears
an important issue in our study because its level condi-
tions whether individuals will seek social support when
they are confronted with unsolvable problems [26]. This
attitude may impact the way they take into account the
messages delivered during our intervention and how they
will adapt their life strategies thereafter. Self-esteem has
also proven to influence the level of hope, with persons
with the higher self-esteem entertaining more hope [27].
Answers are quoted using 4-point Likert scales ran-
ging from “strongly agree” to “strongly disagree.” We ex-
pect that a familial cancer predisposition might lower
self-appraisal and that a more positive regard of it might
contribute to an increase in SES score. The SES has
been validated in French with different samples, includ-
ing people with schizophrenia [28].
State and Trait Anxiety Inventory (STAI-A and STAI-B)
The STAI [11] is a questionnaire widely used to evaluate
anxiety in such a way it cannot be confused with depressive
syndrome. It comprises 40 items rated on a 4-point scale
from “almost never” to “almost always.” The first 20 items
evaluate anxiety as a state, corresponding to a labile/con-
textual aspect. The last 20 items estimate anxiety as a per-
sonality trait, independent of the environment. In our
study, we expect, after our psychoeducational intervention,
a larger change of state anxiety than of trait anxiety. Also,
we assume that a reduction in anxiety will correlate with an
increase in hope (HHI score). The STAI has been translated
into French and validated by Schweitzer and Paulhan [29].
Ways of Coping Checklist
Coping is a wide concept. It can be defined as either a
personality trait (“characteristic ways of responding to
changes of any type in the environment” [30]) or a behav-
ioral characteristic (“a conscious, intentional, goal-directed
response, tailored to the specific demands of a stressor”
[31]). The WCC [12, 13] has been translated into French in
several versions: by Vitaliano (42 items) [32] and, based on
this first translation, one by Schweizer and Paulhan (29
items) [29] and one by Bruchon-Schweitzer (27 items) [33].
We decided to use this last one [33], validated in 2010 in
cancer patients by Cousson-Gélie et al. [34] despite a re-
duced set of 27 items. In the French 27-item version, the 2
main dimensions have been confirmed, characterizing ei-
ther the focus on the problem (10 items) or the focus on
emotions (9 items). A third dimension has been found,
consisting in the search for social support (8 items) [33].
Perceived control (Internal, Powerful Others, and Chance
Locus of Control Scales)
Perceived control synthesizes the equilibrium between
actions launched by the individual and the feedback
returned by the individual’s environment. Levenson’s In-
ternal, Powerful Others, and Chance Locus of Control
Scales (IPC) [14, 35, 36] is one of the most often used
questionnaires to analyze how individuals try to control
their destiny. Locus of control can be perceived either
(1) within the self or (2) outside the self with two ori-
gins: fate/luck and “powerful others.” Depending on the
locus, an individual’s cognition and behaviors vary. In
young women exposed to a high familial cancer risk, the
locus may appear to be outside the self (a BRCA muta-
tion is like a twist of fate). Our intervention will try to
teach how, with adapted behaviors (i.e., mainly changes
in life habits), overall cancer risk can be halved, meaning
that a part of the locus of control dwells, in fact, within
the individual. A low level of perceived control has been
proven to be related to psychological disorders such as
depression [37] as well as a low HHI [22]. The 24-item
IPC has been translated into French by Loas et al. [38].
Quality of life (WHOQOL questionnaire)
QoL is the subjective result of the many interactions
between individuals (including health status) and their
environment. Because it constitutes the focal point of all
these interactions, we thought it might be of interest to
check how our intervention could influence QoL over
the long run. The WHOQOL questionnaire [17] has
been preferred to other validated scales (e.g., European
Organization for Research and Treatment of Cancer
Quality of Life Questionnaire Core 30 for Cancer
[EORTC QLQ-C30] [39], 36-item Short Form Health
Survey [SF-36] [40]) because it does not focus on health-
related QoL. The version used in our study corresponds
to the WHOQOL-BREF (26 items). This version was de-
rived from the 100-item WHOQOL and showed similar
properties. The authors suggested that this short version
could advantageously replace the long version in trials
and surveys investigating QoL [17]. It contains four
main dimensions: physical health, psychological health,
social relationships, and environment. These dimensions
have been confirmed in the French translation by
Leplège et al. [41].
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Methodology
Sample size
Sample size has been determined by taking into account
two factors: first, the need for small groups for the ses-
sions to be efficient (i.e., letting all participants get in-
volved in the exercises and have time to share their
emotions or opinions), and second, the need for the trial
to have sufficient power to evidence differences. Our tar-
get is to objectivize differences between groups of at
least 1 SD of the differential variation in the HHI ques-
tionnaire score between inclusion and 6 months. This
hypothesis is compatible with the results published by
Herth et al. [16], who found that, after a psychosocial
intervention in cancer patients, the improvement to the
global HHI score equaled 9 points with an SD of 9.9. An
expected 1-SD difference may be questioned, however:
Herth’s population corresponded to cancer patients aged
between 20 and 80 years. Our population is healthy, evi-
dently much younger, and includes only females. One of
our expectations is that the study outcome invalidates or
confirms if this reference was relevant; if not, this will
help further studies to build a better-fitting design. With
this 1-SD hypothesis, a one-sided α-risk equal to 0.05,
and 80 % power (β = 0.20), at least 12 participants per
group will have to be accrued. Considering that some
participants may refuse at the last moment to come to
the session, two more participants will be accrued per
arm. Overall, 28 participants need to be included.
Data management
Data will be collected using an electronic case report
form (eCRF). Capture System software (Clinsight,
Cenon, France) will be used to allow participants to
complete their questionnaires by Internet from home.
They will be enabled to input data without the possibil-
ity of consulting their previous answers (questionnaires
at inclusion or at sessions). This blinding is important to
prevent both a back-correction of previous answers and
also to limit the risk of a direct copy for participants
who would avoid recanting. Data will be monitored
according to the specifications defined for this kind
of study; in particular, special attention will be paid
to limit the amount of missing data. Two kinds of
control will be performed using the software. First,
the eCRF will automatically signal if a question is not
answered. However, the participant keeps the right to
confirm the missing item. Second, if an entire ques-
tionnaire is not completed, because this might be an
omission, a message will be sent by the data manager
through the mailing device of the software to ask the
participant to complete the form or to confirm that
she did not forget to fill the questionnaire but
intentionally left it blank.
Data analysis
A statistical analysis plan will be written prior to conduct-
ing any outcome analysis, excluding queries to manage
data. The statistical analysis will start after the database is
locked. This will be done in two steps when the 6-month
and then the 12-month questionnaires are collected.
Data analysis will begin with a description of population
characteristics (age, known BRCA mutation, socioeco-
nomic and educational categories). The balance of these
characteristics will be checked by allocation group. Miss-
ing data will be analyzed by group, by type of question-
naire, and by time (inclusion, sessions, 6 and 12 months).
Further description will present the longitudinal analysis
of questionnaire scores over the course of 1 year. Differ-
ences related to socioeducational and socioeconomic cat-
egorical data and scores at inclusion will be analyzed using
one-way analysis of variance (ANOVA) or Kruskal-Wallis
H test. Overall convergent/divergent analysis between
scores, independently of groups and times, will be verified
by correlation analysis (Pearson’s or Spearman’s correl-
ation if distributions are abnormal). A correspondences
analysis will present the global description of the results
and the relationships between questionnaire dimensions.
The main endpoint will be tested between allocation
groups using individual HHI score variations (change at
6 months from time of inclusion) by Student’s t test or
Mann-Whitney U test if normality/homoscedasticity is
not achieved. All scores by group will be analyzed longi-
tudinally using two-way ANOVA (mixed model) with
either raw scores or their variation from baseline.
The statistical analysis will be performed using SEM
software [42] and R version 3.0.1 software. The SPIRIT
checklist, describing correspondances between the
protocol and standard issues addressed in clinical trial, is
provided as Additional file 1.
Discussion
Prospective, randomized psychoeducational studies are
often difficult to conduct. First, no blinding can be orga-
nized; interventions and group allocations are necessarily
described in the informed consent form. Second, a par-
ticular difficulty is encountered when one tries to precisely
define psychological endpoints; they are usually multiple,
and they influence each other. Third, some endpoints vary
very rapidly shortly after the intervention, but in a labile
way, and a quick positive improvement may hide long-
term inefficacy. However, developing an intervention
without evaluating its effects would lead to a dead end.
To avoid selection bias, randomization using a waiting
list is often the best solution. It ensures that participants
are alike, and it places them on an equal footing. Unfor-
tunately, if the waiting delay is too long, some of the
participants allocated to the waiting list may withdraw
for various personal reasons. We do not expect this to
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happen with our young women; in particular, at such an
age, severe diseases are not that frequent, even in an
HBOC context. Also, a cost-free stay in a spa center
seemed to us attractive enough to limit this possibility.
However, we have decided to increase the sample size a
little so that such events would not reduce the study’s
already limited power (80 %).
The hierarchical structure of our questionnaires is a sec-
ond difficulty. The tendency to multiply the questionnaires
used needs to be fought so that questionnaire completion is
acceptable and can be performed in a short time. Especially
if the completion has to be repeated over time, the missing
data rate can increase, with consequences on estimates.
Also, interactions between the various psychosocial dimen-
sions explored cannot be circumvented easily and may in-
duce confusion bias. Special attention must therefore be
paid to both the complementarity of questionnaires and the
hierarchical validity of studied dimensions. A careful exam-
ination of bibliography was performed, and several expert
discussions between professional psychologists and meth-
odologists were needed before we reached a consensus.
The lability of some psychosocial dimensions makes
them useless to test the effect of an intervention. This
was the case for Rustøen et al. [19] in their study of the
impact of a psychoeducational intervention based on
hope improvement in newly diagnosed cancer patients.
It enabled them to significantly improve the Nowotny
Hope Scale score after 2 weeks, but no gain was noticed
after 6 months. Obviously, in these patients, if chemo-
therapy/radiotherapy is needed and/or if the surgery is
ablative or handicapping, the consequences of the treat-
ments nullify any benefit that might be gained using a
short-term psychosocial intervention. Even without dele-
terious circumstances, short-term improvements that do
not last are very frequent in our context. For example, a
very strong postintervention decrease in Hospital Anxiety
and Depression Scale [43] anxiety score was observed in
another randomized trial testing a 2-week psychoeduca-
tional group intervention. That study addressed patients
with breast cancer previously treated by adjuvant chemo-
therapy, and physical activity and nutrition were the main
topics of the intervention [44]. This immediate improve-
ment of anxiety measured after the intervention was
followed by a return to basal values at 6 months, persist-
ing for the long run. In the present study, our 6-month
primary objective takes into account an assumed stability
of expectations over such a delay in the absence of
intervention and a persistence of the improvement
due to the session—if any—lasting at least 6 months.
In our context, if improvement of scores would last
for a shorter time, the intervention would be of low
interest. The 1-year evaluation constitutes a secondary
endpoint that will enable us to verify whether the 6-
month results are maintained.
Another discussed subject was the “good” time to start
evaluating the intervention. The baseline measure was
initially placed at inclusion. Because the accrual period
will last about 2 months, however, the 6-month delay
would not be respected for participants included early.
We thus decided to shift the questionnaire self-
completion at a fixed time point 2 weeks before the first
session for everybody. Meanwhile, as the provision of so-
cioeconomic data at inclusion might be a good oppor-
tunity to teach the participants how to use our dedicated
website, we decided to reserve a moment after obtaining
the consent signature to explain how to enter the site and
complete the forms. The evolution of the other estimates
and the cross-correlation analysis of questionnaire dimen-
sions will help us to determine if another aspect should be
used instead of the focus on “hope” to improve, with bet-
ter efficacy, the overall QoL of our young women.
Finally, we as yet have no idea how our proposal will
be perceived by our young asymptomatic women. The
rate of refusal and the reasons by which they will justify
their not entering the study will be analyzed and will
help us develop better prevention strategies for the
youngest counselees. One of the purposes of this phase
II trial is to verify the feasibility and acceptability of the
intervention to participants, evaluate its effect size on
the various scales, and prepare a larger national phase
III trial based on a more solid hypothesis. The acceptabil-
ity is of major importance, and a better definition of the
young population that we target may need some adjust-
ments. In particular, the birth of one child does not elim-
inate worries regarding new procreation projects; perhaps
it even increases them as questions about the long-term
security of the child (Will I live long enough to ensure his
future?) are suddenly raised by his arrival. So, the inclu-
sion criteria of our pilot study will probably need to be
widened in a further trial to include young women facing
more concretely not only the transmission dilemma of
their mutation but also familial existential issues.
Trial status
The trial was not started when this article was writ-
ten (October 18th, 2016).
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